Get more information on Heart Failure POC & LOC Devices Market - Request Sample Report
The Heart Failure POC & LOC Devices Market Size was valued at USD 95.94 million in 2023 and is expected to reach USD 401.91 million by 2032 and grow at a CAGR of 17.26% over the forecast period 2024-2032.
In contrast to Lab-On-Chip (LOC) devices, which combine many laboratory activities on a single circuit to allow automation and high throughput screening, Point-of-Care (POC) devices are used to obtain diagnostic data close to the patients. Heart failure can be diagnosed using POC assays, and POC and central lab testing can both be done using LOC device technology. Point-of-care testing finds heart markers and other time-critical indications to address the challenges of health inequities. The global market for POC & LOC devices for heart failure is being driven by reasons including a growth in cardiovascular diseases (CVDs), an increase in the elderly population, and increased R&D for POC & LOC devices. Unfavourable reimbursement practices, however, could impede market expansion during the projection period.
More cardiovascular disorders
The increasing prevalence of cardiovascular disorders creates a significant demand for faster and more accessible diagnostic tools for heart failure.
More R&D is being done for POC and LOC devices
Increase in the elderly population
Ambiguous payment procedures
Ambiguous payment procedures and lack of standardized reimbursement policies can create uncertainty for healthcare providers and hinder widespread adoption of POC/LOC devices.
Increased investment in the study of cardiovascular and heart diseases
Continued investment in research on heart diseases and cardiovascular health can lead to breakthroughs in diagnostics and treatment, further driving the POC/LOC device market.
Creation of more recent, suitable POC and LOC heart failure biomarkers
Lack of knowledge of regulatory requirements
The lack of knowledge or difficulty in navigating complex regulatory requirements can delay market entry for new POC/LOC devices, hindering innovation and market growth.
The Russia Ukraine war has delivered a brutal blow to the country's healthcare system, particularly for those battling heart failure. Hospitals and clinics have been directly targeted, with damaged infrastructure and displaced medical professionals severely limiting their capacity to provide specialized care. Homecare services, crucial for managing chronic heart failure, are also in disarray due to transportation disruptions and population displacement. Specialty centers, offering advanced diagnostics and treatment options, have become less accessible in many war-torn regions.
The impact extends beyond immediate care as advanced diagnostic tools like proteomic, metabolomic, and genomic testing may be less available due to damaged labs, equipment shortages, and a decline in research activities. Ultimately, this war has created a significant setback for Ukrainian heart failure patients, limiting access to potentially life-saving diagnostics and treatment. Rebuilding the healthcare infrastructure and ensuring access to essential services will be paramount in the long-term recovery process.
An economic slowdown threatens to disrupt the heart failure POC & LOC devices market, creating a ripple effect across the healthcare landscape. Hospitals and clinics, facing tighter budgets, may be forced to delay acquiring these advanced diagnostic tools, hindering their ability to diagnose and manage heart failure effectively. Additionally, a potential decline in patient volumes due to cost concerns could further strain their financial resources. Homecare services, which often utilize POC/LOC devices for remote monitoring, could also be negatively impacted. Patients struggling financially may be unable to afford these services, potentially leading to an increase in hospital readmissions as heart failure management at home becomes compromised. Specialty centers, critical for providing advanced diagnostics and treatment for heart failure, are not immune either. Economic downturns could force them to reduce services or staff, limiting access to these vital resources for patients. This would be particularly detrimental for underserved communities who heavily rely on specialty centers.
The impact extends beyond immediate care as advanced diagnostic tools like proteomic, metabolomic, and genomic testing, often expensive, might become less accessible due to funding constraints and potential limitations in insurance coverage this could hinder early detection of heart failure and the ability to tailor treatment plans to individual patients, potentially leading to poorer health outcomes in the long run.
Proteomic Testing
Metabolomic Testing
Genomic Testing
Proteomic testing, accounting for over half with 50.4% of the market share in 2023 this is likely due to the high number of commercially available point-of-care (POC) devices that rely on protein marker testing. However, the metabolomics testing segment is expected to see the fastest growth in the future, with a projected CAGR of 17.8% this suggests it could become a more prominent segment in the coming years.
Microfluidics
Array-based Systems
Microfluidics, accounting for nearly half with 48.8% of the market share in 2023 this technology is projected for the fastest growth 17.5% CAGR due to its rising use in portable biosensors for cardiovascular disease (CVD) screening. These biosensors offer advantages like rapid diagnosis, affordability, and portability compared to traditional lab tests. Microfluidics' ability to miniaturize complex lab functions onto a chip further fuels its dominance, along with efficient use of samples and faster turnaround times. Advancements in microfluidics, particularly paper-based 3D versions, are expected to solidify its position as the leading market segment.
Hospitals &Clinics
Homecare
Specialty Centers
Based on end use is clinics, capturing the largest revenue share of 37.7% in 2023 this dominance is driven by the efficiency of POC testing in various clinic settings, both inpatient (operating rooms, emergency rooms) and outpatient (physician offices, clinics). Clinics are utilizing POC devices extensively for faster and more effective diagnoses, allowing for timely treatment decisions, particularly in managing heart failure this shift towards predictive testing and on-site diagnosis has solidified clinics as the primary driver of the POC testing market. Furthermore, ongoing advancements like AI integration and development of new POC tools and tests are expected to further enhance the efficiency of POC testing in clinics, solidifying their position as the leading end-use segment. The home segment of the POC testing market is poised for explosive growth, with a projected CAGR of 18.3%. This surge is fueled by advancements in Point-of-Care (POC) and Location-Independent Testing (LOC) devices designed with user-friendliness in mind.
REGIONAL COVERAGE
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
The global heart failure POC & LOC devices market is geographically divided, with North America currently leading the pack this dominance can be attributed to the presence of major market players in the US, who significantly contribute to overall revenue growth. A key example is the 2021 business combination agreement between Quidel and Ortho Clinical Diagnostics, which expanded patient access to various diagnostic tools.
However, the Asia Pacific region is poised for the fastest growth at CAGR of 20.5% due to a changing healthcare landscape. Here, the focus is shifting towards managing chronic diseases like heart failure, driven by a rising prevalence of conditions like coronary syndrome and myocardial infarction. Additionally, advancements in medical infrastructure and rising standards of practice are attracting global diagnostic companies to expand their presence in Asia. For instance, Abbott Laboratories generates a significant portion of its revenue from this region. Furthermore, collaborations between global companies and local governments are facilitating market access in countries with lower penetration rates this combined effort is expected to propel the Asia Pacific region to the forefront of the heart failure POC & LOC devices market in the coming years.
Need any customization research on Heart Failure POC & LOC Devices Market - Enquiry Now
Some of the major key players are Abaxis, Inc., bioMérieux S.A, Danaher, Abbott, Siemens Healthineers, Hoffmann-La Roche Ltd., Instrumentation Laboratory Company, Jant Pharmacal Corporation, Quidel Corporation, and Trinity Biotech and Other Players.
Research funded in May 2023 led to the development of the CoDe-ACS algorithm, which utilizes patient data to predict heart attack risk this signifies advancements in diagnostic tools and algorithms.
In May 2022, BioMérieux's acquisition of Specific Diagnostic strengthened their position in clinical microbiology, highlighting a trend of consolidation within the industry.
Ultromics' AI-powered EchoGo device received FDA approval in December 2022, showcasing the growing adoption of artificial intelligence for heart failure detection.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$ 95.94 million |
| Market Size by 2032 | US$ 401.91 million |
| CAGR | CAGR of 17.26% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Test Type (Proteomic Testing, Metabolomic Testing, Genomic Testing) • By Technology (Microfluidics, Array-based Systems) • By End User (Hospitals &Clinics, Homecare, Specialty Centers) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Abaxis, Inc., bioMérieux S.A, Danaher, Abbott, Siemens Healthineers, Hoffmann-La Roche Ltd., Instrumentation Laboratory Company, Jant Pharmacal Corporation, Quidel Corporation, and Trinity Biotech |
| Key Drivers | • More cardiovascular disorders • more R&D is being done for POC and LOC device • Increase in the elderly population |
| RESTRAINTS | • Ambiguous payment procedures |
Ans. The Heart Failure POC & LOC Devices Market is growing at a CAGR of 17.26% over the forecast period 2024-2032.
Ans Increased investment in the study of cardiovascular and heart diseases, Creation of more recent, suitable POC and LOC heart failure biomarkers are the opportunities of the market.
Ans. Heart Failure POC & LOC Devices Market is divided into three segments and they are By Test Type, By Technology, and By End User
Ans. Due to the large market players in North America who are fostering significant organic revenue growth in the worldwide heart failure POC & LOC devices market, the region led the revenue share
Ans. Proteomic Testing, Metabolomic Testing, and Genomic Testing are sub segments of by test type of the Heart Failure POC & LOC Devices Market.
TABLE OF CONTENTS
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Industry Flowchart
3. Research Methodology
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
5. Impact Analysis
5.1 Impact of Russia-Ukraine Crisis
5.2 Impact of Economic Slowdown on Major Countries
5.2.1 Introduction
5.2.2 United States
5.2.3 Canada
5.2.4 Germany
5.2.5 France
5.2.6 UK
5.2.7 China
5.2.8 Japan
5.2.9 South Korea
5.2.10 India
6. Value Chain Analysis
7. Porter’s 5 Forces Model
8. Pest Analysis
9. Heart Failure POC & LOC Devices Market Segmentation, By Test Technology
9.1 Introduction
9.2 Trend Analysis
9.3 Proteomic Testing
9.4 Metabolomic Testing
9.5 Genomic Testing
10. Heart Failure POC & LOC Devices Market Segmentation, By Technology
10.1 Introduction
10.2 Trend Analysis
10.3 Microfluidics
10.4 Array-based Systems
11. Heart Failure POC & LOC Devices Market Segmentation, By End User
11.1 Introduction
11.2 Trend Analysis
11.3 Hospitals &Clinics
11.4 Homecare
11.5 Specialty Centers
12. Regional Analysis
12.1 Introduction
12.2 North America
12.2.1 Trend Analysis
12.2.2 North America Heart Failure POC & LOC Devices Market by Country
12.2.3 North America Heart Failure POC & LOC Devices Market By Test Technology
12.2.4 North America Heart Failure POC & LOC Devices Market By Technology
12.2.5 North America Heart Failure POC & LOC Devices Market By End User
12.2.6 USA
12.2.6.1 USA Heart Failure POC & LOC Devices Market By Test Technology
12.2.6.2 USA Heart Failure POC & LOC Devices Market By Technology
12.2.6.3 USA Heart Failure POC & LOC Devices Market By End User
12.2.7 Canada
12.2.7.1 Canada Heart Failure POC & LOC Devices Market By Test Technology
12.2.7.2 Canada Heart Failure POC & LOC Devices Market By Technology
12.2.7.3 Canada Heart Failure POC & LOC Devices Market By End User
12.2.8 Mexico
12.2.8.1 Mexico Heart Failure POC & LOC Devices Market By Test Technology
12.2.8.2 Mexico Heart Failure POC & LOC Devices Market By Technology
12.2.8.3 Mexico Heart Failure POC & LOC Devices Market By End User
12.3 Europe
12.3.1 Trend Analysis
12.3.2 Eastern Europe
12.3.2.1 Eastern Europe Heart Failure POC & LOC Devices Market by Country
12.3.2.2 Eastern Europe Heart Failure POC & LOC Devices Market By Test Technology
12.3.2.3 Eastern Europe Heart Failure POC & LOC Devices Market By Technology
12.3.2.4 Eastern Europe Heart Failure POC & LOC Devices Market By End User
12.3.2.5 Poland
12.3.2.5.1 Poland Heart Failure POC & LOC Devices Market By Test Technology
12.3.2.5.2 Poland Heart Failure POC & LOC Devices Market By Technology
12.3.2.5.3 Poland Heart Failure POC & LOC Devices Market By End User
12.3.2.6 Romania
12.3.2.6.1 Romania Heart Failure POC & LOC Devices Market By Test Technology
12.3.2.6.2 Romania Heart Failure POC & LOC Devices Market By Technology
12.3.2.6.4 Romania Heart Failure POC & LOC Devices Market By End User
12.3.2.7 Hungary
12.3.2.7.1 Hungary Heart Failure POC & LOC Devices Market By Test Technology
12.3.2.7.2 Hungary Heart Failure POC & LOC Devices Market By Technology
12.3.2.7.3 Hungary Heart Failure POC & LOC Devices Market By End User
12.3.2.8 Turkey
12.3.2.8.1 Turkey Heart Failure POC & LOC Devices Market By Test Technology
12.3.2.8.2 Turkey Heart Failure POC & LOC Devices Market By Technology
12.3.2.8.3 Turkey Heart Failure POC & LOC Devices Market By End User
12.3.2.9 Rest of Eastern Europe
12.3.2.9.1 Rest of Eastern Europe Heart Failure POC & LOC Devices Market By Test Technology
12.3.2.9.2 Rest of Eastern Europe Heart Failure POC & LOC Devices Market By Technology
12.3.2.9.3 Rest of Eastern Europe Heart Failure POC & LOC Devices Market By End User
12.3.3 Western Europe
12.3.3.1 Western Europe Heart Failure POC & LOC Devices Market by Country
12.3.3.2 Western Europe Heart Failure POC & LOC Devices Market By Test Technology
12.3.3.3 Western Europe Heart Failure POC & LOC Devices Market By Technology
12.3.3.4 Western Europe Heart Failure POC & LOC Devices Market By End User
12.3.3.5 Germany
12.3.3.5.1 Germany Heart Failure POC & LOC Devices Market By Test Technology
12.3.3.5.2 Germany Heart Failure POC & LOC Devices Market By Technology
12.3.3.5.3 Germany Heart Failure POC & LOC Devices Market By End User
12.3.3.6 France
12.3.3.6.1 France Heart Failure POC & LOC Devices Market By Test Technology
12.3.3.6.2 France Heart Failure POC & LOC Devices Market By Technology
12.3.3.6.3 France Heart Failure POC & LOC Devices Market By End User
12.3.3.7 UK
12.3.3.7.1 UK Heart Failure POC & LOC Devices Market By Test Technology
12.3.3.7.2 UK Heart Failure POC & LOC Devices Market By Technology
12.3.3.7.3 UK Heart Failure POC & LOC Devices Market By End User
12.3.3.8 Italy
12.3.3.8.1 Italy Heart Failure POC & LOC Devices Market By Test Technology
12.3.3.8.2 Italy Heart Failure POC & LOC Devices Market By Technology
12.3.3.8.3 Italy Heart Failure POC & LOC Devices Market By End User
12.3.3.9 Spain
12.3.3.9.1 Spain Heart Failure POC & LOC Devices Market By Test Technology
12.3.3.9.2 Spain Heart Failure POC & LOC Devices Market By Technology
12.3.3.9.3 Spain Heart Failure POC & LOC Devices Market By End User
12.3.3.10 Netherlands
12.3.3.10.1 Netherlands Heart Failure POC & LOC Devices Market By Test Technology
12.3.3.10.2 Netherlands Heart Failure POC & LOC Devices Market By Technology
12.3.3.10.3 Netherlands Heart Failure POC & LOC Devices Market By End User
12.3.3.11 Switzerland
12.3.3.11.1 Switzerland Heart Failure POC & LOC Devices Market By Test Technology
12.3.3.11.2 Switzerland Heart Failure POC & LOC Devices Market By Technology
12.3.3.11.3 Switzerland Heart Failure POC & LOC Devices Market By End User
12.3.3.1.12 Austria
12.3.3.12.1 Austria Heart Failure POC & LOC Devices Market By Test Technology
12.3.3.12.2 Austria Heart Failure POC & LOC Devices Market By Technology
12.3.3.12.3 Austria Heart Failure POC & LOC Devices Market By End User
12.3.3.13 Rest of Western Europe
12.3.3.13.1 Rest of Western Europe Heart Failure POC & LOC Devices Market By Test Technology
12.3.3.13.2 Rest of Western Europe Heart Failure POC & LOC Devices Market By Technology
12.3.3.13.3 Rest of Western Europe Heart Failure POC & LOC Devices Market By End User
12.4 Asia-Pacific
12.4.1 Trend Analysis
12.4.2 Asia-Pacific Heart Failure POC & LOC Devices Market by Country
12.4.3 Asia-Pacific Heart Failure POC & LOC Devices Market By Test Technology
12.4.4 Asia-Pacific Heart Failure POC & LOC Devices Market By Technology
12.4.5 Asia-Pacific Heart Failure POC & LOC Devices Market By End User
12.4.6 China
12.4.6.1 China Heart Failure POC & LOC Devices Market By Test Technology
12.4.6.2 China Heart Failure POC & LOC Devices Market By Technology
12.4.6.3 China Heart Failure POC & LOC Devices Market By End User
12.4.7 India
12.4.7.1 India Heart Failure POC & LOC Devices Market By Test Technology
12.4.7.2 India Heart Failure POC & LOC Devices Market By Technology
12.4.7.3 India Heart Failure POC & LOC Devices Market By End User
12.4.8 Japan
12.4.8.1 Japan Heart Failure POC & LOC Devices Market By Test Technology
12.4.8.2 Japan Heart Failure POC & LOC Devices Market By Technology
12.4.8.3 Japan Heart Failure POC & LOC Devices Market By End User
12.4.9 South Korea
12.4.9.1 South Korea Heart Failure POC & LOC Devices Market By Test Technology
12.4.9.2 South Korea Heart Failure POC & LOC Devices Market By Technology
12.4.9.3 South Korea Heart Failure POC & LOC Devices Market By End User
12.4.10 Vietnam
12.4.10.1 Vietnam Heart Failure POC & LOC Devices Market By Test Technology
12.4.10.2 Vietnam Heart Failure POC & LOC Devices Market By Technology
12.4.10.3 Vietnam Heart Failure POC & LOC Devices Market By End User
12.4.11 Singapore
12.4.11.1 Singapore Heart Failure POC & LOC Devices Market By Test Technology
12.4.11.2 Singapore Heart Failure POC & LOC Devices Market By Technology
12.4.11.3 Singapore Heart Failure POC & LOC Devices Market By End User
12.4.12 Australia
12.4.12.1 Australia Heart Failure POC & LOC Devices Market By Test Technology
12.4.12.2 Australia Heart Failure POC & LOC Devices Market By Technology
12.4.12.3 Australia Heart Failure POC & LOC Devices Market By End User
12.4.13 Rest of Asia-Pacific
12.4.13.1 Rest of Asia-Pacific Heart Failure POC & LOC Devices Market By Test Technology
12.4.13.2 Rest of Asia-Pacific Heart Failure POC & LOC Devices Market By Technology
12.4.13.3 Rest of Asia-Pacific Heart Failure POC & LOC Devices Market By End User
12.5 Middle East & Africa
12.5.1 Trend Analysis
12.5.2 Middle East
12.5.2.1 Middle East Heart Failure POC & LOC Devices Market by Country
12.5.2.2 Middle East Heart Failure POC & LOC Devices Market By Test Technology
12.5.2.3 Middle East Heart Failure POC & LOC Devices Market By Technology
12.5.2.4 Middle East Heart Failure POC & LOC Devices Market By End User
12.5.2.5 UAE
12.5.2.5.1 UAE Heart Failure POC & LOC Devices Market By Test Technology
12.5.2.5.2 UAE Heart Failure POC & LOC Devices Market By Technology
12.5.2.5.3 UAE Heart Failure POC & LOC Devices Market By End User
12.5.2.6 Egypt
12.5.2.6.1 Egypt Heart Failure POC & LOC Devices Market By Test Technology
12.5.2.6.2 Egypt Heart Failure POC & LOC Devices Market By Technology
12.5.2.6.3 Egypt Heart Failure POC & LOC Devices Market By End User
12.5.2.7 Saudi Arabia
12.5.2.7.1 Saudi Arabia Heart Failure POC & LOC Devices Market By Test Technology
12.5.2.7.2 Saudi Arabia Heart Failure POC & LOC Devices Market By Technology
12.5.2.7.3 Saudi Arabia Heart Failure POC & LOC Devices Market By End User
12.5.2.8 Qatar
12.5.2.8.1 Qatar Heart Failure POC & LOC Devices Market By Test Technology
12.5.2.8.2 Qatar Heart Failure POC & LOC Devices Market By Technology
12.5.2.8.3 Qatar Heart Failure POC & LOC Devices Market By End User
12.5.2.9 Rest of Middle East
12.5.2.9.1 Rest of Middle East Heart Failure POC & LOC Devices Market By Test Technology
12.5.2.9.2 Rest of Middle East Heart Failure POC & LOC Devices Market By Technology
12.5.2.9.3 Rest of Middle East Heart Failure POC & LOC Devices Market By End User
12.5.3 Africa
12.5.3.1 Africa Heart Failure POC & LOC Devices Market by Country
12.5.3.2 Africa Heart Failure POC & LOC Devices Market By Test Technology
12.5.3.3 Africa Heart Failure POC & LOC Devices Market By Technology
12.5.3.4 Africa Heart Failure POC & LOC Devices Market By End User
12.5.3.5 Nigeria
12.5.3.5.1 Nigeria Heart Failure POC & LOC Devices Market By Test Technology
12.5.3.5.2 Nigeria Heart Failure POC & LOC Devices Market By Technology
12.5.3.5.3 Nigeria Heart Failure POC & LOC Devices Market By End User
12.5.3.6 South Africa
12.5.3.6.1 South Africa Heart Failure POC & LOC Devices Market By Test Technology
12.5.3.6.2 South Africa Heart Failure POC & LOC Devices Market By Technology
12.5.3.6.3 South Africa Heart Failure POC & LOC Devices Market By End User
12.5.3.7 Rest of Africa
12.5.3.7.1 Rest of Africa Heart Failure POC & LOC Devices Market By Test Technology
12.5.3.7.2 Rest of Africa Heart Failure POC & LOC Devices Market By Technology
12.5.3.7.3 Rest of Africa Heart Failure POC & LOC Devices Market By End User
12.6 Latin America
12.6.1 Trend Analysis
12.6.2 Latin America Heart Failure POC & LOC Devices Market by country
12.6.3 Latin America Heart Failure POC & LOC Devices Market By Test Technology
12.6.4 Latin America Heart Failure POC & LOC Devices Market By Technology
12.6.5 Latin America Heart Failure POC & LOC Devices Market By End User
12.6.6 Brazil
12.6.6.1 Brazil Heart Failure POC & LOC Devices Market By Test Technology
12.6.6.2 Brazil Heart Failure POC & LOC Devices Market By Technology
12.6.6.3 Brazil Heart Failure POC & LOC Devices Market By End User
12.6.7 Argentina
12.6.7.1 Argentina Heart Failure POC & LOC Devices Market By Test Technology
12.6.7.2 Argentina Heart Failure POC & LOC Devices Market By Technology
12.6.7.3 Argentina Heart Failure POC & LOC Devices Market By End User
12.6.8 Colombia
12.6.8.1 Colombia Heart Failure POC & LOC Devices Market By Test Technology
12.6.8.2 Colombia Heart Failure POC & LOC Devices Market By Technology
12.6.8.3 Colombia Heart Failure POC & LOC Devices Market By End User
12.6.9 Rest of Latin America
12.6.9.1 Rest of Latin America Heart Failure POC & LOC Devices Market By Test Technology
12.6.9.2 Rest of Latin America Heart Failure POC & LOC Devices Market By Technology
12.6.9.3 Rest of Latin America Heart Failure POC & LOC Devices Market By End User
13. Company Profiles
13.1 Abaxis, Inc.
13.1.1 Company Overview
13.1.2 Financial
13.1.3 Test Technology/ Services Offered
13.1.4 SWOT Analysis
13.1.5 The SNS View
13.2 bioMérieux S.A
13.2.1 Company Overview
13.2.2 Financial
13.2.3 Test Technology / Services Offered
13.2.4 SWOT Analysis
13.2.5 The SNS View
13.3 Danaher
13.3.1 Company Overview
13.3.2 Financial
13.3.3 Test Technology / Services Offered
13.3.4 SWOT Analysis
13.3.5 The SNS View
13.4 Abbott
13.4.1 Company Overview
13.4.2 Financial
13.4.3 Test Technology / Services Offered
13.4.4 SWOT Analysis
13.4.5 The SNS View
13.5 Siemens Healthineers
13.5.1 Company Overview
13.5.2 Financial
13.5.3 Test Technology/ Services Offered
13.5.4 SWOT Analysis
13.5.5 The SNS View
13.6 Hoffmann-La Roche Ltd.
13.6.1 Company Overview
13.6.2 Financial
13.6.3 Test Technology/ Services Offered
13.6.4 SWOT Analysis
13.6.5 The SNS View
13.7 Instrumentation Laboratory Company
13.7.1 Company Overview
13.7.2 Financial
13.7.3 Test Technology/ Services Offered
13.7.4 SWOT Analysis
13.7.5 The SNS View
13.8 Jant Pharmacal Corporation
13.8.1 Company Overview
13.8.2 Financial
13.8.3 Test Technology/ Services Offered
13.8.4 SWOT Analysis
13.8.5 The SNS View
13.9 Quidel Corporation
13.9.1 Company Overview
13.9.2 Financial
13.9.3 Test Technology/ Services Offered
13.9.4 SWOT Analysis
13.9.5 The SNS View
13.10 Trinity Biotech
13.10.1 Company Overview
13.10.2 Financial
13.10.3 Test Technology/ Services Offered
13.10.4 SWOT Analysis
13.10.5 The SNS View
14. Competitive Landscape
14.1 Competitive Benchmarking
14.2 Market Share Analysis
14.3 Recent Developments
14.3.1 Industry News
14.3.2 Company News
14.3.3 Mergers & Acquisitions
15. Use Case and Best Practices
16. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Blood Group Typing Market was estimated at USD 1.9 billion in 2023 and is poised to reach 4.05 billion in 2032 anticipated to expand at a compound annual growth rate of 8.8% for the forecast period of 2024-2032.
The Pharmacovigilance market valued USD 7.20 billion in 2023, and estimated to reach USD 18.52 billion by 2032 with CAGR 11.09% over the forecast period 2024-2032.
The Leukapheresis Market Size was valued at USD 192 billion in 2023 and is expected to reach USD 491.05 billion by 2032 and grow at a CAGR of 11.01% over the forecast period 2024-2032.
The Functional Endoscopic Sinus Surgery Market Size was valued at USD 1.01 Billion in 2023, and is expected to reach USD 1.91 Billion by 2032, and grow at a CAGR of 7.66% over the Forecast Period of 2024-2032.
The Dialysis Market was valued at USD 98.55 Bn in 2023 and is expected to reach USD 190.53 Bn by 2032 and grow at a CAGR of 7.6% over the forecast period of 2024-2032.
The Bilirubin Blood Test Market Size was valued at USD 1.18 billion in 2023, and is expected to reach USD 2.11 billion by 2032, and grow at a CAGR of 6.7% over the forecast period 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
